Adverum Biotechnologies, Inc. ADVM · Stock Open Adverum Biotechnologies, Inc. in new tab
Adverum Biotechnologies, Inc. Analysis (ADVM)
Is Adverum Biotechnologies, Inc. a good investment? Adverum Biotechnologies, Inc. (ADVM) is currently trading at 4.36 USD. Market analysts have a consensus price target of 29.71 USD. This suggests a potential upside from current levels.
Earnings Schedule: Adverum Biotechnologies, Inc. is expected to release its next earnings report on April 21, 2026. The market consensus estimate for Forward EPS is -5.33.
Investor FAQ
Does Adverum Biotechnologies, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Adverum Biotechnologies, Inc.?
Adverum Biotechnologies, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 21, 2026. The company currently has a trailing EPS of -5.95.
Company Profile
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Split Date | Split Ratio to 1 |
|---|---|
| March 21, 2024 | 1:10 |
Community Discussion